Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter

3

hyperintensity volume: A cross-sectional study

Jose Bernal^{1,2,T}, Stefanie Schreiber^{2,3,T}, Inga Menze^{1,2}, Anna Ostendorf¹, Malte Pfister³, Jonas 4 Geisendörfer³, Aditya Nemali^{1,2}, Anne Maass², Renat Yakupov², Oliver Peters^{4,5}, Lukas 5 Preis⁵, Luisa Schneider⁵, Ana Lucia Herrera⁵, Josef Priller^{4,6,7,8}, Eike Jakob Spruth^{4,6}, Slawek 6 Altenstein^{4,6}, Anja Schneider^{9,10}, Klaus Fliessbach^{9,10}, Jens Wiltfang^{11,12,13}, Björn 7 H.Schott^{11,12}, Ayda Rostamzadeh¹⁴, Wenzel Glanz¹, Katharina Buerger^{16,17}, Daniel 8 Janowitz¹⁷, Michael Ewers^{16,17}, Robert Perneczky^{18,19,20,21,33}, Boris-Stephan Rauchmann¹⁹, 9 Stefan Teipel^{22,23}, Ingo Kilimann^{22,23}, Christoph Laske^{24,25}, Matthias H. Munk^{24,26}, Annika 10 Spottke^{9,10}, Nina Roy⁹, Laura Dobisch², Peter Dechent²⁷, Klaus Scheffler²⁸, Stefan Hetzer²⁹, 11 Steffen Wolfsgruber^{9,10}, Luca Kleineidam^{9,10}, Matthias Schmid^{9, 30}, Moritz Berger³⁰, Frank 12 Jessen^{9,14,15}, Miranka Wirth³¹, Emrah Düzel^{1,2,32,†}, Gabriel Ziegler^{1,2,†} 13

- 14 ^T Shared first authorship
- 15 [†]Shared last authorship

16 Author affiliations:

- ¹⁷ ¹Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University
- 18 Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany
- ¹⁹ ²German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44,
- 20 39120 Magdeburg, Germany
- ³Department of Neurology, University Hospital Magdeburg, Medical Faculty, Leipziger Str.
- 22 44, 39120 Magdeburg, Germany

23 4	German	Center for N	Neurodegenerat	tive Diseases	(DZNE).	Berlin,	Germany

- ⁵Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
- 25 Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany
- ²⁶ ⁶Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin,
- 27 Germany
- 28 ⁷School of Medicine, Technical University of Munich; Department of Psychiatry and
- 29 Psychotherapy, Munich, Germany
- ⁸University of Edinburgh and UK DRI, Edinburgh, UK
- ⁹German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1,
 53127 Bonn, Germany
- ³³ ¹⁰University of Bonn Medical Center, Dept. of Neurodegenerative Disease and Geriatric
- 34 Psychiatry/Psychiatry, Venusberg-Campus 1, 53127 Bonn, Germany
- ¹¹German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- ¹²Department of Psychiatry and Psychotherapy, University Medical Center Goettingen,
- 37 University of Goettingen, Von-Siebold-Str. 5, 37075 Goettingen
- ¹³Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of
- 39 Medical Sciences, University of Aveiro, Aveiro, Portugal
- 40 ¹⁴Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62,
- 41 50924 Cologne, Germany
- 42 ¹⁵Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),
- 43 University of Cologne, Joseph-Stelzmann-Strasse 26, 50931 Köln, Germany

- 44 ¹⁶German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse
- 45 17, 81377 Munich, Germany
- 46 ¹⁷Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich,
- 47 Feodor-Lynen-Strasse 17, 81377 Munich, Germany
- 48 ¹⁸German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse
- 49 17, 81377 Munich, Germany
- ¹⁹Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich,
- 51 Germany
- ⁵² ²⁰Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany
- ⁵³ ²¹Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College
- 54 London, London, UK
- ²²German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
- ²³Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer
- 57 Str. 20, 18147 Rostock
- ⁵⁸ ²⁴German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany
- ²⁵Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department
- 60 of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
- ⁶¹²⁶Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
- 62 ²⁷MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-
- 63 University Goettingen, Germany
- ²⁸Department for Biomedical Magnetic Resonance, University of Tübingen, 72076 Tübingen,
- 65 Germany

66	²⁹ Berlin	Center	for	Advanced	Neuroimaging,	Charité -	Universitätsmedizin	Berlin,	Berlin,
----	----------------------	--------	-----	----------	---------------	-----------	---------------------	---------	---------

67 Germany

- ³⁰Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn,
- 69 Venusberg-Campus 1, D-53127 Bonn
- ³¹German Center for Neurodegenerative Diseases (DZNE), Dresden, Tatzberg 41, 01307
- 71 Dresden, Germany
- ³²Institute of Cognitive Neuroscience, University College London, London, UK
- ³³Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield,
- 74 Sheffield, UK

75

- 76 Correspondence to: Jose Bernal & Miranka Wirth
- Full address: German Centre for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger
- 78 Str. 44, 39120 Magdeburg, Germany & German Centre for Neurodegenerative Diseases
- 79 (DZNE), Dresden, Tatzberg 41, 01307 Dresden, Germany
- 80 E-mail: jose.bernalmoyano@dzne.de & miranka.wirth@dzne.de

81 Abbreviations

- 82 A β β -amyloid
- 83 AD Alzheimer's disease
- 84 ATN Amyloid/Tau/Neurodegeneration
- 85 B regression coefficient

- 86 CAA Cerebral amyloid angiopathy
- 87 CERAD Consortium to Establish a Registry for Alzheimer's Disease
- 88 CN Non-complaining healthy controls
- 89 CSF Cerebrospinal fluid
- 90 CSVD Cerebral small vessel disease
- 91 FDR False discovery rate
- 92 FLAIR Fluid Attenuated Inversion Recovery
- 93 GM Grey matter
- 94 IQR Interquartile range
- 95 MCI Mild cognitive impairment
- 96 MRI Magnetic resonance imaging
- 97 NC Normal cognition
- 98 PACC5 Preclinical Alzheimer's Cognitive Composite 5
- 99 ROI Region of interest
- 100 SCD Subjective cognitive decline
- 101 SD Standard deviation
- 102 SE Standard error
- 103 SPM Statistical parametric mapping
- 104 TICV Total intracranial volume
- 105 WM White matter

106 WMH White matter hyperintensities

107 Abstract

108 Background

109 Posterior white matter hyperintensities (WMH) in subjects across the Alzheimer's disease 110 (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just 111 arterial hypertension—impacts WMH, adversely influencing cognition. Here we seek to 112 determine the effect of both hypertension and A β positivity on WMH, and their impact on 113 cognition.

114 Methods

115 We analysed data from subjects with a low vascular profile and normal cognition (NC), 116 subjective cognitive decline (SCD), and amnestic mild cognitive impairment (MCI) enrolled 117 in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and 118 Dementia Study (n=375, median age 70.2 [IQR 66.0-74.4] years; 176 female; NC/SCD/MCI 119 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on 120 baseline memory and executive function-derived from multiple neuropsychological tests 121 using confirmatory factor analysis—, baseline preclinical Alzheimer's cognitive composite 5 122 (PACC5) scores, and changes in PACC5 scores over course of three years (Δ PACC5).

123 **Results**

Subjects with hypertension or A β positivity presented the largest WMH volumes ($p_{FDR}<0.05$), with spatial overlap in the frontal (hypertension: 0.42±0.17; A β : 0.46±0.18), occipital (hypertension: 0.50±0.16; A β : 0.50±0.16), parietal lobes (hypertension: 0.57±0.18; A β : 0.56±0.20), corona radiata (hypertension: 0.45±0.17; A β : 0.40±0.13), optic radiation

128 (hypertension: 0.39 ± 0.18 ; A β : 0.74 ± 0.19), and splenium of the corpus callosum 129 (hypertension: 0.36 ± 0.12 ; A β : 0.28 ± 0.12). Hypertension, A β positivity, and WMH were 130 connected to cognition. First, WMH coincided with worse cognitive performance and 131 outcomes (p_{FDR} <0.05), regardless of A β and hypertension. Accelerated cognitive decline was 132 associated with WMH in the genu of the corpus callosum and segments of the forceps major 133 and inferior fronto-occipital longitudinal fasciculus (p_{FDR} <0.05). Second, hypertension was 134 indirectly linked to cognitive performance at baseline and over time via splenial WMH 135 (*indirect-only effect*; memory: -0.05 ± 0.02 , $p_{FDR}=0.029$; executive: -0.04 ± 0.02 , $p_{FDR}=0.067$; 136 PACC5: -0.05 \pm 0.02, p_{FDR} =0.030; Δ PACC5: -0.09 \pm 0.03, p_{FDR} =0.043). Third, the relationship 137 between A β positivity and baseline and longitudinal cognitive performance was independent 138 of WMH burden.

139 Conclusions

140 Posterior white matter is susceptible to hypertension and A β accumulation and it mediates the 141 association between hypertension and cognitive dysfunction. Posterior WMH could be a 142 promising target to tackle the downstream damage related to the potentially interacting and 143 potentiating effects of the two pathologies.

144 **Trial Registration**

145 German Clinical Trials Register (DRKS00007966, 04/05/2015)

146

147 Keywords: white matter hyperintensities; vascular risk; Alzheimer's disease; cognitive
148 performance; MRI

149 Background

The term "cerebral white matter hyperintensities" (WMH) describes dynamic and diffuse microstructural alterations in both periventricular and deep white matter, which appear hypodense on computed tomography and hyperintense on T2-weighted magnetic resonance imaging (MRI) and coincide with demyelination, axon loss, and gliosis [1,2]. WMH are common—especially but not exclusively in old age—and relate to a large spectrum of clinical symptoms, including apathy, fatigue, delirium, depression, progressive cognitive impairment, physical function disturbances, and increased risk of dementia and stroke [2,3].

157 Alterations to the functioning of cerebral micro-vessels—also known as cerebral small vessel 158 disease (CSVD)—caused, for instance, by long-term exposure to cardiovascular risk factors 159 (hypertension particularly) have been assumed to drive WMH formation [4–6]. Nonetheless, 160 recent studies demonstrating elevated global and posterior WMH in patients along the 161 Alzheimer's disease (AD) spectrum with minimal vascular pathology (for review see [1,7–9]) 162 call into question the assumption that any "AD-related" WMH solely reflect a vascular 163 contribution. This viewpoint has also been challenged by studies reporting a more "AD-like" 164 WMH pattern in A β positive subjective cognitive decline (SCD), mild cognitive impairment 165 (MCI) or AD. The "AD-like" pattern is roughly confined to deep and periventricular posterior 166 regions comprising the (parieto-)occipital lobe, corona radiata, optic (thalamic) radiation, or 167 the corpus callosum (especially splenium) and presents neuropathologically with underlying 168 gliosis, and axonal and myelin loss, but minimal vascular pathology-likely occurring 169 secondary to cortical neurodegeneration [7-10]. Further studies demonstrate frontal or 170 temporoparietal WMH dominance in AD as well and others report mixed results on the 171 relationship between posterior WMH and AD pathology [11–14]. "WMH of presumed

172 vascular origin" are, however, usually depicted in deep and periventricular frontal areas,

173 suggesting some spatial WMH heterogeneity in hypertension compared to AD [8,15].

Here we use region- and voxel-based lesion analysis to determine the effect of both hypertension and AD pathology, i.e. β -amyloid (A β) positivity, on WMH as well as their interacting impact on cognition. For that purpose, we study WMH of non-demented participants of a large multicentre cohort with available cerebrospinal fluid (CSF) AD biomarkers, history of hypertension, and cross-sectional as well as longitudinal neuropsychological tests.

180 Methods

181 Study design

182 We used baseline MRI, CSF AD biomarkers, cognitive performance scores, medical records 183 and longitudinal cognitive performance scores from the DELCODE (DZNE Longitudinal 184 Cognitive Impairment and Dementia Study) cohort, an observational multicentre study from 185 the German Centre for Neurodegenerative Diseases (DZNE) that focuses on the multimodal 186 assessment of preclinical and clinical AD stages [16]. All participants received an extensive 187 assessment at the local study site prior to joining DELCODE, which included medical 188 history, psychiatric and neurological examination, neuropsychological testing, blood 189 laboratory work-up, and routine MRI in accordance with local standards. All memory clinics 190 used the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 191 neuropsychological test battery [17] to assess cognitive function. We focused on non-192 complaining healthy controls with normal cognition (NC) and participants with SCD and

MCI and excluded patients with dementia due to AD to enrich our sample by variance due tovascular disease and Aβ pathology.

195 The presence of SCD and amnestic MCI was diagnosed using the existing research criteria 196 for SCD [18,19] and MCI [20], respectively. Participants were diagnosed with SCD if they 197 reported subjective cognitive decline or memory concerns, as expressed to the physician of 198 the memory centre, and had a test performance better than -1.5 standard deviations (SD) 199 below the age, sex, and education-adjusted normal performance on all subtests of the 200 CERAD battery. The MCI group consisted of participants with amnestic MCI, as defined by 201 age, sex, and education-adjusted performance below -1.5 SD on the delayed recall trial of the 202 CERAD word-list episodic memory tests.

The NC group was recruited through local newspaper advertisements. Individuals who responded to the advertisement were screened by telephone with regard to SCD. The control group had to achieve unimpaired cognitive performance according to the same definition as the SCD group.

207 All participants entered DELCODE based on either their clinical diagnosis derived from the 208 clinical workup or their identification as a control subject according to the procedures 209 outlined. Additional inclusion criteria for all groups were age ≥ 160 years, fluent German 210 language skills, capacity to provide informed consent, and presence of a study partner. The 211 main exclusion criteria for all groups were conditions clearly interfering with participation in 212 the study or the study procedures, including significant sensory impairment. The following 213 medical conditions were considered exclusion criteria: current major depressive episode, 214 major psychiatric disorders either at baseline or in the past (e.g., psychotic disorder, bipolar 215 disorder, substance abuse), neurodegenerative disorder other than AD, vascular dementia, 216 history of stroke with residual clinical symptoms, history of malignant disease, severe or

unstable medical conditions, and clinically significant laboratory abnormalities in vitamin B12. Prohibited drugs included chronic use of psychoactive compounds with sedative or anticholinergic effects, use of anti-dementia agents in SCD, amnestic MCI, and control subjects, and investigational drugs for the treatment of dementia or cognitive impairment one month before entry and throughout the duration of the study.

222 All participants gave written informed consent before inclusion in the study. DELCODE is

223 retrospectively registered at the German Clinical Trials Register (DRKS00007966,

224 04/05/2015) and was approved by ethical committees and local review boards.

225 Hypertension

Medical records were retrospectively screened for cardiovascular risk factors at the time of MRI. Patients diagnosed before to have primary or secondary arterial hypertension were considered to suffer from arterial hypertension (1: hypertensive; 0: normotensive). Single blood pressure measurements were not taken into account since repeated, long-term or athome measurements would be required for the final diagnosis [21].

231 Cognitive performance

232 All participants underwent a rich neuropsychological assessment, comprising the Mini-233 Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive 13-234 item subscale (ADAS-Cog 13), the Free and Cued Selective Reminding Test (FCRST; 235 including a serial subtraction task, Wechsler Memory Scale revised version (WMS-R), 236 Logical Memory [Story A] and Digit Span), two semantic fluency tasks (animals and 237 groceries), the Boston Naming Test (15-item short version analogue to the CERAD battery, 238 supplemented by five infrequent items from the long version), the oral form of the Symbol-239 Digit-Modalities Test (including a subsequent free recall of symbols and symbol-digit

pairings), Trail Making Test Parts A and B, Clock Drawing and Clock Copying, a recall task of previously copied figures (as in the CERAD test battery), the Face Name Associative Recognition Test, and a Flanker task to assess executive control of attention. We focused on memory and executive function at baseline derived from these neuropsychological tests using confirmatory factor analysis to reduce the influence of test-specific effects and measurement errors [22].

246 We also leveraged the Preclinical Alzheimer's Disease Cognitive Composite (PACC5) [23], 247 which provides a single outcome measure reflective of episodic memory, timed executive 248 function, and global cognition; domains that have been found sensitive to amyloid pathology. 249 The PACC5 score was calculated as the mean of an individual's z-standardised performance 250 in the FCSRT Free Recall and Total Recall, the MMSE, the WMS-R Logical Memory Story 251 A Delayed Recall, the Symbol-Digit-Modalities Test, and the sum of the two category 252 fluency tasks and used the baseline mean and SD values of the cognitively unimpaired group 253 of our sample to derive the subtest z-scores.

We selected subjects with available PACC5 scores over three annual follow-ups for further analysis. We estimated rates of change in these PACC5 scores over time using a linear mixed effect model (ΔPACC5 from hereon). We expressed it as follows:

$$PACC5_{ij} = X_{ij}\beta + Z_{ij}b_i + \epsilon_{ij}, \qquad (1)$$

where $PACC5_{ij}$ is the PACC5 scores of subject $i \in [1, N]$ at visit $j \in [1, t]$; $X_{ij} \in \mathbb{R}^{N \times p}$ a matrix of the p predictor variables; $\beta \in \mathbb{R}^{p}$ a vector of fixed-effects regression coefficients; $Z_{ij} \in \mathbb{R}^{N \times q}$ a design matrix for the q random effects; $b_i \in \mathbb{R}^{q}$ a vector of random effects; and ϵ_{ij} the within-subject measurement errors. The fixed effects structure include clinical group structure measured at baseline and their corresponding interaction with time (t_{ij}) . The fixed effects include age, sex and education taken at baseline.

263 Structural MRI

264 Structural MRI scans were acquired at nine German DZNE sites on Siemens MR scanners 265 (including three TIM Trio, four Verio, one Skyra, and one Prisma system). We used T1-266 weighted MPRAGE images (3D GRAPPA PAT 2, 1 mm³ isotropic, 256×256 , 192 sagittal 267 slices, repetition time 2500 ms, echo time 4.33 ms, inversion time 1100 ms, flip angle 7° , ~5 268 min acquisition time) and T2-weighted 3D FLAIR images (GRAPPA PAT factor 2, 1 mm³ 269 isotropic, 256×256 , 192 sagittal slices, repetition time 5000 ms, echo time 394 ms, inversion 270 time 1800 ms, ~7 min acquisition time). Standard operating procedures, quality assurance 271 and assessment were provided and supervised by the DZNE imaging network (iNET, 272 Magdeburg) as described in [16]. We computed the mean background intensity as a surrogate 273 measure of image quality and motion artefacts [24,25] and adjusted statistical models for it, 274 as the quality of the scans determine also segmentation performance [26-28].

275 Biomarker characterisation

276 Trained study assistants carried out lumbar punctures for 49% of all DELCODE participants. 277 CSF samples were centrifuged, aliquoted and stored at -80°C for retests. Biomarkers known 278 to mirror AD pathology (CSF Aβ42 and Aβ40) were determined by commercially available 279 kits (V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E)). Each participant was classified as 280 normal (-) or abnormal (+) with regard to amyloid levels based on the A β 42/40 ratio, 281 independently of their phosphorylated Tau (pTau) status, in line with the ATN classification 282 system. Cut-offs (A β negative: A β 42/40 >0.08; A β positive: A β 42/40 \leq 0.08) were calculated 283 from DELCODE using the Gaussian mixture modelling in the R-package flexmix (v2.3-15) 284 (for details see [16,29]).

285 WMH segmentation and spatial processing

286 We processed baseline T1-weighted and FLAIR scans as follows. We performed bias field 287 inhomogeneity correction, skull stripping, and segmentation using the Multi-Brain (MB) 288 toolbox in statistical parametric mapping (SPM) [30]. We segmented grey matter (GM), 289 white matter (WM), and CSF from T1-weighted scans with MB and identified WMH 290 probability maps from FLAIR scans using the Lesion Prediction Algorithm in the Lesion 291 Segmentation Toolbox [31]. We then used MB for normalising tissue classes (and WMH 292 maps) to a DELCODE-specific MB template. We adjusted for local volume changes 293 introduced by the normalisation in GM and WMH probability maps by modulation with 294 Jacobian determinants [30,32]. Finally, we smoothed WMH maps with Gaussian kernels (6 295 mm full width at half maximum). Processing results of all steps were carefully checked 296 visually and statistically using covariance-based tools provided in Computational Anatomy 297 Toolbox 12 (CAT12) [33].

298 **ROI-based processing**

We extracted WMH volume from 12 regions of interest (ROI) in cerebral WM, as described in detail in a previous study [11]. In brief, we created ROIs in accordance with the STRIVE criteria [34] and included the four lobes of the brain, four major WM tracks and three sections of the corpus callosum and a global cerebral WM mask. We calculated WMH volumes for each ROI and adjusted for total intracranial volume (TICV). All computations were conducted in the template space.

305 A schematic overview both processing and analysis methods is illustrated in Figure S1.

306 Statistical analyses

307 **Relationship between hypertension and A\beta positivity**

308 We tested for associations between hypertension and A β positivity given their potential 309 collinearity [35–38] using the Pearson's Chi-squared test with Yates' continuity correction in 310 the R-package *stats* (v3.6.2).

Effects of hypertension and Aβ **positivity on WMH**

312 We hypothesised that a history of hypertension and an abnormal build-up of A β relate 313 positively to the volume of WMH, but that both conditions display distinct spatial effects: 314 hypertension on deep and periventricular frontal regions and A β on deep and periventricular 315 posterior regions, as discussed in the literature [1,4-9]. We used a 2×2 ANCOVA model in 316 CAT12 to examine the relationship between WMH segmentation maps (outcome) and 317 hypertension and A β (factors) at a voxel level. Similarly, to probe the same relationship at an 318 ROI level, we built 2×2 ANCOVA models in R (stats, v3.6.2), one for each region of interest 319 separately. We controlled for covariates and confounders (see 'Covariates, confounders, and 320 data transformation' below).

321 Effects of WMH on cognitive performance

Our hypothesis was that cognitive performance declined and rates of change in cognition increased as voxel-wise and regional WMH increased, in agreement with previous findings [2,3]. For voxel-based analysis, we used multiple linear regression in CAT12 with WMH segmentation maps as the dependent variable and cognitive performance as the independent variable. Likewise, for each region of interest, we also used multiple linear regression in R (stats, v3.6.2) to probe the relationship between regional WMH volume and cognition. We created different models with memory, executive function, PACC5, and Δ PACC5 as

dependent variables. Note that, for studying the effect of baseline WMH on change in cognition, we leveraged summary statistics (Δ PACC5) instead of using a linear mixed effect model to keep the mass univariate analysis efficient [39] and both the voxel- and region-wise analyses consistent. We controlled for hypertension and A β positivity in addition to covariates and confounders (see '*Covariates, confounders, and data transformation*' below).

334 Mediation models

Assuming that long-term exposure to hypertension and A β build-up has a negative effect on the integrity of the white matter and that its damage—depicted in the form of regional WMH—impacts cognition negatively, we hypothesise that there is an indirect effect of hypertension and A β on cognition that is mediated by WMH volume, in line with theoretical considerations [5,6,40,41] (**Figure 1**). We used the R-package lavaan (v0.6-11) and followed the steps for mediation analysis suggested by Hair *et al.* [42] Significance was assessed using 95% confidence intervals generated by bias-corrected bootstrap with 1000 replicates.

342 **Covariates, confounders, and data transformation**

We adjusted all models for covariates (age, sex, years of education) and confounders (TICV) and mean background intensity to reduce biases brought in by correlated regressors. To account for collinearity between TICV and sex, we chose "overall mean" as "centring" for TICV and leveraged global scaling for this confounder. We refrained from adjusting our analyses for clinical groups to avoid collinearity issues with A β positivity (namely, A β positivity was more frequent in MCI vs NC and SCD). We log-transformed regional WMH volumes to account for skewness.

16

350 Explicit mask

- 351 We used an explicit mask to constrain the analysis to voxels in which data for at least five
- 352 patients were available.

353 **Correction for multiple comparisons**

- 354 We adjusted *p*-values for multiple comparisons using the false discovery rates (FDR)
- approach to deal with the problem of multiple comparisons.[43]

356 **Results**

357 Sample description

We included baseline data of 375 subjects out of 1079 recruited for DELCODE after quality control and assessing the availability of CSF biomarkers and MRI (Figure S2; median age 70.0 [IQR 66.0-74.0] years, 46.9% female, median years of education 13 [IQR 12-17]; European origins). Δ PACC5 was only available for a subset (n=226/375). Demographics and global WMH volumes stratified by hypertension and A β positivity are summarised in **Table 1**. We found no significant association between arterial hypertension and A β positivity $(X^2=2.1302, p=0.1444)$.

365	$Table \ 1 \ Demographics \ and \ WMH \ volume, \ stratified \ by \ hypertension \ diagnosis \ and \ A\beta \ positivity \ (n=375)^a$
-----	---

Group	Subjects n (%)	Age in years Median [IQR]	Female n (%)	Education in years Median [IQR]	WMH volume in ml ^b Median [IQR]
Hypertension	202 (53.9)	72 [67, 75]	89 (23.7)	13 [12, 17]	1.87 [0.83, 5.83]
Normotension	173 (46.1)	69 [64, 72]	87 (23.2)	14 [13, 17]	1.19 [0.45, 2.78]
Aβ positive	132 (35.2)	72 [68, 76]	55 (14.7)	13 [12, 17]	2.39 [1.11, 6.32]
Aβ negative	243 (64.8)	68 [65, 73]	121 (32.2)	13 [13, 17]	1.16 [0.55, 2.96]

³⁶⁶ 367 368

^aGlobal WMH volumes are higher subjects with hypertension vs normotension (W=13744, p<0.001) and A β positive vs negative (W=11851, p<0.001); age differences between groups explain, to a certain extent, these outcomes (hypertension vs normotension: W=13014, p<0.001; A β positive vs A β negative: W=10186, p<0.001)

^bUnadjusted WMH volumes in ml

n sample size

IQR interquartile range

373 WMH are associated with both arterial hypertension and $A\beta$

374 **positivity**

375 We initially investigated WMH in relation to hypertension and A β positivity. We observed 376 that the global volume of WMH was a fourth greater in subjects with either a history of 377 hypertension vs normotension (26% [95%-CI 5%, 52%]) or a positive vs negative A β status 378 (25% [95%-CI 3%, 52%]) (Table 2). Regional variations in the frontal, parietal, and 379 occipital—not temporal—lobes contributed to this outcome; regression coefficients for both 380 hypertension and A β positivity were comparable in these three regions (**Table 2**). In posterior 381 regions of the brain, we found that the relationship between WMH and hypertension was 382 clearer than that between WMH and $A\beta$ positivity in the splenium of the corpus callosum 383 (Figure 2 and Table 2); the opposite was true in the optic radiation (Figure 2 and Table 2; 384 peak: between forceps major and inferior fronto-occipital fasciculus).

385 Table 2. Subjects with hypertension and Aβ positivity present the largest frontal, parietal, and occipital WMH volumes^b

	XX75.6XX 1 8	Hypertension		Aβ positivity		
	WMH volume ^a	B (SE)	p_{FDR}	B (SE)	p_{FDR}	
	Global	0.23 (0.09)	0.030	0.22 (0.10)	0.044	
	Frontal	0.42 (0.17)	0.021	0.46 (0.18)	0.021	
Lobes	Temporal	0.14 (0.14)	0.447	0.22 (0.15)	0.268	
Lobes	Occipital	0.50 (0.16)	0.003	0.50 (0.16)	0.004	
	Parietal	0.57 (0.18)	0.005	0.56 (0.20)	0.008	
	Corona radiata	0.45 (0.17)	0.020	0.40 (0.13)	0.046	
T	External capsule	0.21 (0.13)	0.171	0.27 (0.13)	0.096	
Tracts	Internal capsule	0.22 (0.14)	0.209	0.07 (0.15)	0.741	
	Optic radiation	0.39 (0.18)	0.041	0.74 (0.19)	0.001	
	Genu	0.23 (0.11)	0.087	0.07 (0.12)	0.641	
Corpus callosum	Body	0.21 (0.10)	0.053	0.15 (0.10)	0.212	
	Splenium	0.36 (0.12)	0.005	0.28 (0.12)	0.038	

³⁸⁶ 387

^aWe log-transformed WMH volumes to deal with skewness

^bWe built multiple linear regression models to examine regional WMH volume (outcome) in relation to hypertension and A β positivity (factors)—one for each region of interest separately. We controlled for age, sex, education, mean background intensity, and total intracranial volume. We print $p_{FDR} < 0.05$ in bold.

91 p_{FDR} p-values after adjusting for multiple comparisons using FDR

92 B regression coefficient

393 SE standard error

394

395 WMH are negatively associated with cognitive performance and

396 outcomes

397 We then investigated whether cognitive performance and outcomes were associated with 398 WMH (Figure 3 and Table 3). We found a significant association between global WMH 399 volumes and worse baseline cognitive performance and a sharper cognitive decline over the 400 course of three years, regardless of hypertension diagnosis and A β positivity (**Table 3**). 401 Evidence for such a connection was present in most regions of interest, except in the external 402 capsule. Such relationships were consistently evident around portions of the anterior thalamic 403 radiation neighbouring the thalamus (Figure 3). In frontal and occipital regions, we also saw 404 a significant link between WMH and quicker cognitive deterioration (Figure 3 - frontal peak 405 at the level of the genu of the corpus callosum; occipital peak at the level of the forceps major 406 and inferior fronto-occipital longitudinal fasciculus).

407 Table 3. Higher WMH volumes are associated with worse and worsening cognitive performance^b

		Baseline (n=375)	Longitudinal (n=226)			
	WMH volume ^a	Memory	Executive	PACC5	$\Delta PACC5$ B (SE); p_{FDR}	
		B (SE); p_{FDR}	B (SE); p_{FDR}	B (SE); p_{FDR}		
	Global	-0.10 (0.03); <0.001	-0.08 (0.03); 0.005	-0.10 (0.03); 0.001	-0.16 (0.05); 0.001	
	Frontal	-0.04 (0.05); 0.012	-0.03 (0.02); 0.028	-0.04 (0.02); 0.008	-0.09 (0.03); 0.004	
Lobes	Temporal	-0.07 (0.02); 0.001	-0.05 (0.02); 0.007	-0.07 (0.02); <0.001	-0.13 (0.04); <0.001	
	Occipital	-0.04 (0.02); 0.006	-0.02 (0.02); 0.335	-0.03 (0.02); 0.078	-0.10 (0.03); 0.001	
	Parietal	-0.04 (0.01); 0.002	-0.03 (0.01); 0.040	-0.04 (0.01); 0.005	-0.06 (0.03); 0.025	
	Corona radiata	-0.05 (0.01); 0.001	-0.04 (0.02); 0.008	-0.05 (0.02); 0.003	-0.08 (0.03); 0.004	
Tracts	External capsule	-0.03 (0.02); 0.142	-0.00 (0.02); 0.893	-0.03 (0.02); 0.107	-0.07 (0.04); 0.103	
Tra	Internal capsule	-0.05 (0.02); 0.004	-0.05 (0.02); 0.005	-0.06 (0.02); 0.002	-0.08 (0.03); 0.016	
-	Optic radiation	-0.05 (0.01); 0.001	-0.02 (0.01); 0.198	-0.04 (0.01); 0.010	-0.09 (0.03); 0.001	
Corpus callosum	Genu	-0.07 (0.02); 0.004	-0.04 (0.02); 0.057	-0.06 (0.02); 0.016	-0.11 (0.04); 0.004	
	Body	-0.11 (0.03); <0.001	-0.10 (0.03); <0.001	-0.11 (0.03); <0.001	-0.16 (0.05); 0.001	
	Splenium	-0.10 (0.02); <0.001	-0.08 (0.02); 0.001	-0.10 (0.02); <0.001	-0.13 (0.04); 0.002	

 $[\]begin{array}{r} 408 \\ 409 \\ 410 \\ 411 \\ 412 \\ 413 \\ 414 \\ 415 \\ 416 \\ 417 \end{array}$

^aWe log-transformed WMH volumes to deal with skewness

^bFor each region of interest, we used multiple linear regression to probe the relationship between regional WMH volume and cognitive performance. We created different models with baseline (memory, executive function, and PACC5) and longitudinal (\triangle PACC5) cognitive performance as dependent variables. We adjusted for hypertension, A β positivity, age, sex, education, mean background intensity, and total intracranial volume. We print *p*_{FDR} < 0.05 in bold.

 p_{FDR} *p*-values after adjusting for multiple comparisons using FDR

15 n sample size

B regression coefficient

417 SE standard error

418

419 The effect of $A\beta$ positivity on cognition does not depend on WMH,

420 **but that of hypertesion does**

421 Our final assessment consisted of determining whether A β positivity or hypertension were 422 associated with cognition (Table 4). Despite the lack of evidence for a direct association 423 between hypertension and cognitive performance, we found hypertension to be indirectly 424 linked to both worse performance at baseline and a steeper deterioration over the course of 425 three years via splenial WMH (regression coefficient \pm standard error; memory: -0.05 \pm 0.02, 426 p_{FDR} =0.029; executive: -0.04±0.02, p_{FDR} =0.067; PACC5: -0.05±0.02, p_{FDR} =0.030; Δ PACC5: 427 -0.09 ± 0.03 , $p_{FDR}=0.043$). On the other hand, the association between AB positivity and 428 baseline and longitudinal cognitive performance (memory: -0.33 ± 0.08 , $p_{FDR} < 0.001$; 429 executive: -0.21 ± 0.08 , $p_{FDR}<0.001$; PACC5: -0.29 ± 0.09 , $p_{FDR}=0.006$; Δ PACC5: -0.34 ± 0.04 , 430 $p_{FDR} < 0.05$) was independent of its association with regional WMH volumes (no grounds for 431 mediation in general, as shown in Table 2).

432 **Discussion**

433 Using data from a large multi-site cohort of older adults along the AD spectrum (n=375), we 434 investigated the impact of arterial hypertension and A β positivity on WMH and cognition. 435 Our data suggest that (i) both hypertension and A β positivity are associated with increased 436 volume of WMH at both voxel and regional levels, (ii) WMH are strongly associated with 437 poor cognitive performance and outcomes, (iii) posterior WMH have a role in the association 438 between hypertension and cognitive performance at baseline and over time, and (iv) the 439 relationship between $A\beta$ positivity and cognition does not depend on WMH. 440 We observed a posterior WMH dominance in Aβ-positive older adults in the predementia 441 stage of the AD continuum. Global and posterior WMH presence and volume were

442 nonetheless the largest when both $A\beta$ retention and hypertension occurred simultaneously 443 and the smallest when none of them did. The posterior white matter could therefore be 444 considered vulnerable to the independent yet interacting and potentiating effects of AD 445 pathology and hypertension-related CSVD. One could thus consider posterior WMH to be a 446 structural correlate that underlies the common observations that vascular disease, in particular 447 hypertension, lowers the threshold for all-cause dementia development in face of pre-existing 448 AD pathology, and vice versa [4-6]. As posterior WMH dominance could also relate to 449 cerebrovascular deposition of A β , i.e. cerebral amyloid angiopathy (CAA), a condition that 450 highly overlaps with AD pathology (for review see [44,45]), we visually inspected 451 susceptibility-weighted sequences of all MRIs. Isolated lobar haemorrhagic markers were 452 found in less than 10% (of them 19 were diagnosed with possible and 4 with probable CAA 453 according to the Boston criteria [46,47]) of participants, making a relevant impact of CAA on 454 posterior WMH in our sample highly unlikely.

455 WMH can negatively impact cognitive function, but associations with memory have been 456 less consistent compared to associations with executive function (for review see [48]). With 457 the exception of the external capsule, we found rather substantial evidence for associations 458 between WMH and worse cognitive performance, likewise affecting memory and executive 459 function, and outcomes (Table 3). Intriguingly, hypertension was associated with executive, 460 memory, and baseline and longitudinal global cognitive function only via splenial WMH, a 461 white matter structure responsible for cognitive processing and a hub where distinct 462 pathologies impact the neural circuitries interconnecting the temporal and occipital regions of 463 both cerebral hemispheres [7,49–51]. White matter damage in this region, as associated with 464 cardiovascular risk, could be expected to translate to lower cognitive functioning in global 465 cognition but also in discrete domains [7]. In previous studies though, posterior/splenial 466 WMH have been found associated with executive (including attention), but not memory

467 function [7,10]. Differences may arise from WMH quantification methods and/or smaller 468 sample sizes including AD patients only (not individuals with SCD/MCI), in whom largely 469 advanced (medial temporal lobe) AD pathology is the major driver for memory decline, 470 possibly "diluting" concurrent memory effects of posterior WMH.

471 Contrary to our expectations and to strong evidence from large longitudinal population-based 472 studies (for review see [6]), we did not see a direct effect of hypertension effect on cognition 473 but rather an indirect-only effect via splenial WMH. This finding might reflect a selection 474 bias of the DELCODE study: exclusion of individuals with advanced vascular disease, which 475 would likewise result in the exclusion of those with severe and uncontrolled hypertension. 476 This constellation, additionally, explains the somewhat lower prevalence of arterial 477 hypertension (nearly 54% compared to 63%), with a slightly higher number of A β positives 478 (35% compared to a range of 17% to 34%) compared to that in population-based cohorts 479 aged over 60 years [52–54]. Our definition of arterial hypertension was based on 480 retrospective screening of medical records for already existing hypertension diagnoses, which 481 might have missed those participants with recently, i.e. newly, diagnosed hypertension after 482 baseline MRI, also contributing to lower prevalence.

483 This study has limitations. First, our imaging results are cross-sectional. While our findings 484 suggest WMH are indeed spatially associated with both hypertension and A β positivity, they 485 do not address causality (e.g. vascular risk first, impaired brain drainage second). 486 Longitudinal analysis of DELCODE imaging data might provide further insights into the 487 influence of lifestyle over time and help disentangle the mixed effects observed in this cross-488 sectional study. Second, our mediation model investigates whether WMH volume can 489 mediate the association between A β and hypertension on cognitive function. While this 490 choice was based on a theoretical consideration [5,6,40,41], a model where the AD and 491 CSVD pathologies (here as A β accumulation and WMH burden) cyclically contribute to each

492 other would also be feasible [2,5,55]. Third, the study of WMH probability patterns in other 493 cohorts of individuals (e.g. whose origins are other than European; DELCODE participants 494 are predominantly of European origins) with a high vascular but low AD profile or vice versa 495 could be informative on the mechanisms leading to these findings in a more general way. 496 Further, we did not consider WMH patterns, which could be punctuated or confluent, for 497 example, or the clinically established distinction between deep and periventricular WMH.

498 Conclusion

499 Our work points toward a large spatial overlap between the effect of arterial hypertension and 500 A β build-up on WMH, with both constellations considered risk factors for white matter 501 damage. At the same time, our work calls into question whether posterior WMH are a core 502 feature related to AD pathology, alternatively suggesting that posterior white matter is 503 vulnerable to both vascular and amyloid pathologies. While the effect of A β on cognition 504 would seem rather independent of WMH, posterior WMH seem to play a role in the 505 association between arterial hypertension and poor cognitive performance and outcomes; it 506 could be a promising target to tackle the downstream damage related to the interacting and 507 potentiating effect of multiple pathologies.

508 **Declarations**

509 Ethics approval and consent to participate

All participants gave written informed consent before inclusion in the study. DELCODE is retrospectively registered at the German Clinical Trials Register (DRKS00007966, 04/05/2015) and was approved by ethical committees and local review boards.

513 Consent for publication

514 Not applicable.

515 Availability of data and materials

- 516 The datasets used and analysed during the current study are available from the corresponding
- 517 author on reasonable request.

518 Competing interests

519 The authors report no competing interests.

520 Funding

- 521 This research was supported by the German Center for Neurodegenerative Diseases
- 522 (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE; reference number BN012)
- 523 and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG;
- 524 Project IDs 425899996 and 362321501/RTG 2413 SynAGE). The funding bodies played no
- role in the design of the study or collection, analysis, or interpretation of data or in writing themanuscript.

527 Author's contributions

- 528 Conceptualisation: JB, SS, MW, GZ. Methodology: JB, SS, MW, GZ. Software: JB, GZ.
- 529 Formal analysis: JB. DELCODE study design: ED, AS, and FJ. Image processing: JB, GZ,
- 530 RY, MW. Image analysis and modelling: JB, GZ. Investigation: JB, SS, MW, GZ. Writing
- 531 original draft preparation: JB, SS, MW, GZ. Writing review and editing: All authors.

532 Acknowledgements

We would like to express our gratitude to all DELCODE participants. We also thank the Max-Delbrück-centrum für Molekulare medizin in der Helmholtz-Gemeinschaft (MDC), Freie Universität Berlin Center for Cognitive neuroscience Berlin (CCNB), Bernstein Center für Computional Neuroscience Berlin, Universitätsmedizin Göttingen Core Facility MR-Research Göttingen, Institut für Klinische Radiologie Klinikum der Universität München,

538 and Universitätsklinikum Tübingen MR-Forschungszentrum.

539 **References**

- Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, et al. White matter
 hyperintensities in vascular contributions to cognitive impairment and dementia (VCID):
 Knowledge gaps and opportunities. Alzheimer's Dement Transl Res Clin Interv. Elsevier
 Inc.; 2019;5:107–17.
- 544 2. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical
 545 implications. Lancet Neurol. Elsevier Ltd; 2019;18:684–96.
- 546 3. Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal FN, Wardlaw JM.
- 547 Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic
- review and meta-analysis. The Lancet Psychiatry. Elsevier Ltd; 2021;8:225–36.
- 549 4. Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. Association of Cumulative Blood Pressure
- 550 With Cognitive Decline, Dementia, and Mortality. J Am Coll Cardiol. 2022;79:1321–35.
- 551 5. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, et al. Hypertension-
- 552 induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol.
- 553 Springer US; 2021;17:639–54.
- 6. Palta P, Albert MS, Gottesman RF. Heart health meets cognitive health: evidence on the

role of blood pressure. Lancet Neurol. Elsevier Ltd; 2021;20:854–67.

- 556 7. Garnier-Crussard A, Bougacha S, Wirth M, Dautricourt S, Sherif S, Landeau B, et al.
- 557 White matter hyperintensity topography in Alzheimer's disease and links to cognition.
- 558 Alzheimer's Dement. 2022;18:422–33.
- 559 8. Pålhaugen L, Sudre CH, Tecelao S, Nakling A, Almdahl IS, Kalheim LF, et al. Brain
- 560 amyloid and vascular risk are related to distinct white matter hyperintensity patterns. J Cereb
- 561 Blood Flow Metab. 2021;41:1162–74.
- 562 9. Desmarais P, Gao AF, Lanctôt K, Rogaeva E, Ramirez J, Herrmann N, et al. White matter
- 563 hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer's
- 564 disease. Alzheimer's Res Ther. Alzheimer's Research & Therapy; 2021;13:1–16.
- 565 10. Huynh K, Piguet O, Kwok J, Dobson-Stone C, Halliday GM, Hodges JR, et al. Clinical
- and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-
- 567 Variant Frontotemporal Dementia and Alzheimer Disease. Neurology. 2021;96:e1743–54.
- 568 11. Gaubert M, Lange C, Garnier-Crussard A, Köbe T, Bougacha S, Gonneaud J, et al.
- 569 Topographic patterns of white matter hyperintensities are associated with multimodal
- 570 neuroimaging biomarkers of Alzheimer's disease. Alzheimer's Res Ther. Alzheimer's
- 571 Research & Therapy; 2021;13:1–11.
- 572 12. Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, et al.
 573 Cerebral amyloid burden is associated with white matter hyperintensity location in specific
- 574 posterior white matter regions. Neurobiol Aging. Elsevier Inc; 2019;84:225–34.
- 575 13. McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, et al. Cortical tau
- 576 load is associated with white matter hyperintensities. Acta Neuropathol Commun. Acta
- 577 Neuropathologica Communications; 2015;3:60.
- 578 14. Englund E. Neuropathology of white matter changes in Alzheimer's disease and vascular
- 579 dementia. Dement Geriatr Cogn Disord. 1998;9:6–12.

580	15. Habes M, Sotiras A, Erus G, Toledo JB, Janowitz D, Wolk DA, et al. White matter
581	lesions spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy.
582	Neurology. 2018;91:E964–75.
583	16. Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, et al. Design and first
584	baseline data of the DZNE multicenter observational study on predementia Alzheimer's
585	disease (DELCODE). Alzheimer's Res Ther. Alzheimer's Research & Therapy; 2018;10:1-
586	10.

- 17. Morris J, Heyman A, Mohs R, Hughes M, van Belle G, Fillenbaum G, et al. Consortium
 to Establish a Registry on Alzheimer's Disease (CERAD). Part I. Clinical and
 neuropsychological assessment of Alzheimer's disease. Encycl Clin Neuropsychol.
 2018;940–4.
- 18. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al.
 Implementation of subjective cognitive decline criteria in research studies. Alzheimer's
 Dement. 2017;13:296–311.
- 594 19. Jessen F, Amariglio RE, Van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A
 595 conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's
- 596 disease. Alzheimer's Dement. 2014;10:844–52.
- 20. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The
 diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from
 the National Institute on Aging-Alzheimer's Association workgroups on diagnostic
 guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:270–9.
- 601 21. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al.
- 602 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for
- 603 the prevention, detection, evaluation, and management of high blood pressure in adults a
- 604 report of the American College of Cardiology/American Heart Association Task Force on

- 605 Clinical pr. Hypertension. 2018.
- 606 22. Wolfsgruber S, Kleineidam L, Guski J, Polcher A, Frommann I, Roeske S, et al. Minor
- 607 neuropsychological deficits in patients with subjective cognitive decline. Neurology.

608 2020;95:e1134–43.

- 609 23. Papp K V., Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical
- 610 Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimer's
- 611 Dement Transl Res Clin Interv. Elsevier Inc.; 2017;3:668–77.
- 612 24. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC:
- 613 Advancing the automatic prediction of image quality in MRI from unseen sites. PLoS One.
- 614 2017;12:1–21.
- 615 25. Esteban O, Blair RW, Nielson DM, Varada JC, Marrett S, Thomas AG, et al.
- 616 Crowdsourced MRI quality metrics and expert quality annotations for training of humans and
- 617 machines. Sci Data [Internet]. Springer US; 2019;6:1-7. Available from:
- 618 http://dx.doi.org/10.1038/s41597-019-0035-4
- 619 26. Lutti A, Corbin N, Ashburner J, Ziegler G, Phillips C, Kherif F, et al. Restoring statistical
- 620 validity in group analyses of motion- corrupted MRI data. Hum Brain Mapp. 2022;43:1973–
- 621 83.
- 622 27. Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L, Douaud G,
- 623 et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from
- 624 UK Biobank. Neuroimage. 2018;166:400–24.
- 625 28. Bernal J, Valdés-Hernández MDC, Escudero J, Duarte R, Ballerini L, Bastin ME, et al.
- 626 Assessment of perivascular space filtering methods using a three-dimensional computational
- 627 model. Magn Reson Imaging. 2022;93:33–51.
- 628 29. Jessen F, Wolfsgruber S, Kleineindam L, Spottke A, Altenstein S, Bartels C, et al.
- 629 Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory

- 630 centers. Alzheimer's Dement. 2022;1–11.
- 631 30. Brudfors M, Flandin G, Nachev P, Ashburner J. Flexible Bayesian Modelling for
- 632 Nonlinear Image Registration Mikael. Med Image Comput Comput Assist Interv Conf 2020
- 633 Lect Notes Comput Sci. Springer Nature Switzerland AG; 2020. p. 253–63.
- 634 31. Schmidt P, Wink L. LST : A lesion segmentation tool for SPM. 2019.
- 635 32. Ashburner J, Friston KJ. Diffeomorphic registration using geodesic shooting and Gauss-
- 636 Newton optimisation. Neuroimage. Elsevier Inc.; 2011;55:954–67.
- 637 33. Gaser C, Dahnke R. CAT A computational anatomy toolbox for the analysis of
- 638 structural MRI data. [1] C Gaser R Dahnke, "GaserHBM2016," vol 32, no 7, p 7743, 2012.
- 639 2012;32:7743.
- 640 34. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al.
- 641 Neuroimaging standards for research into small vessel disease and its contribution to ageing
- and neurodegeneration. Lancet Neurol. Elsevier Ltd; 2013;12:822–38.
- 643 35. Braun M, Iliff JJ. The impact of neurovascular, blood-brain barrier, and glymphatic
- 644 dysfunction in neurodegenerative and metabolic diseases. 1st ed. Int. Rev. Neurobiol.
- 645 Elsevier Inc.; 2020.
- 646 36. Brickman AM, Tosto G, Gutierrez J, Andrews H, Gu Y, Narkhede A, et al. An MRI
- 647 measure of degenerative and cerebrovascular pathology in Alzheimer disease. Neurology.
- 648 2018;91:E1402–12.
- 649 37. Cai Z, Wang C, He W, Tu H, Tang Z, Xiao M, et al. Cerebral small vessel disease and
- Alzheimer's disease. Clin Interv Aging. 2015;10:1695–704.
- 651 38. Iturria-Medina Y, Hachinski V, Evans AC. The vascular facet of late-onset Alzheimer's
- disease: An essential factor in a complex multifactorial disorder. Curr Opin Neurol.2017;30:623–9.
- 654 39. Guillaume B, Hua X, Thompson PM, Waldorp L, Nichols TE. Fast and accurate

- modelling of longitudinal and repeated measures neuroimaging data. Neuroimage [Internet].
- 656 Elsevier B.V.; 2014;94:287–302. Available from:
- 657 http://dx.doi.org/10.1016/j.neuroimage.2014.03.029
- 40. Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing-Implications in
- 659 hypertension. J Mol Cell Cardiol [Internet]. The Authors; 2015;83:112–21. Available from:
- 660 http://dx.doi.org/10.1016/j.yjmcc.2015.04.011
- 41. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease:
- 662 Clinical Insights and Vascular Mechanisms. Can J Cardiol [Internet]. The Authors;
- 663 2018;34:575–84. Available from: https://doi.org/10.1016/j.cjca.2017.12.005
- 42. Hair JF, Hult GTM, Ringle CM, Sarstedt M, Danks NP, Ray S. Mediation Analysis.
- 665 Partial Least Squares Struct. Equ. Model. Using R. Springer, Cham; 2021.
- 43. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful
- approach to multiple testing. J R Stat Soc Ser B. JSTOR; 1995;289–300.
- 44. Charidimou A, Boulouis G, Haley K, Auriel E, Van Etten ES, Fotiadis P, et al. White
- 669 matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy.
- 670 Neurology. 2016;86:505–11.
- 45. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Velow
- 672 SJ. Cerebral amyloid angiopathy and Alzheimer disease one peptide, two pathways
- 673 Steven. Nat Rev Neurol. 2020;16:30–42.
- 46. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of
- 675 superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74:1346–
- 676 50.
- 47. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy evolution of the
- 678 Boston criteria. Stroke. 2018;49:491–7.
- 48. Roseborough AD, Saad L, Goodman M, Cipriano LE, Hachinski VC, Whitehead SN.

680 White matter hyperintensities and longitudinal cognitive decline in cognitively normal 681 populations and across diagnostic categories: A meta-analysis, systematic review, and 682 recommendations for future study harmonization. Alzheimer's Dement. 2022;1–14.

- 683 49. Altermatt A, Gaetano L, Magon S, Bauer L, Feurer R, Gnahn H, et al. Clinical
- associations of T2-weighted lesion load and lesion location in small vessel disease: Insights
- from a large prospective cohort study. Neuroimage. Elsevier Ltd; 2019;189:727–33.
- 50. Kimura Y, Kitagawa K, Oku N, Kajimoto K, Kato H, Tanaka M, et al. Blood Pressure
- 687 Lowering with Valsartan Is Associated with Maintenance of Cerebral Blood Flow and
- 688 Cerebral Perfusion Reserve in Hypertensive Patients with Cerebral Small Vessel Disease. J
- 689 Stroke Cerebrovasc Dis. Elsevier Ltd; 2010;19:85–91.
- 690 51. Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas D, et al. Extent and
- distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology.2006;67:2192–8.
- 693 52. Keuss SE, Coath W, Nicholas JM, Poole T, Barnes J, Cash DM, et al. Associations of β -
- 694 Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal
- 695 Members of the 1946 British Birth Cohort Neurology ® Published Ahead of Print articles
- have been peer reviewed and accepted for publication . This manuscr. Neurology. 2022;1–38.
- 697 53. Krell-Roesch J, Vassilaki M, Mielke MM, Kremers WK, Lowe VJ, Vemuri P, et al.
- 698 Cortical β -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo
- 699 Clinic Study of Aging. Transl Psychiatry. Springer US; 2019;9.
- 54. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence
- and Control Among Adults: United States, 2015-2016. NCHS Data Brief. 2017;1–8.
- 55. Maillard P, Seshadri S, Beiser A, Himali JJ, Au R, Fletcher E, et al. Effects of systolic
- blood pressure on white-matter integrity in young adults in the Framingham Heart Study: A
- ross-sectional study. Lancet Neurol. 2012;11:1039–47.
 - 31

705

706 Figure legends

Figure 1. Model investigating direct and indirect (via WMH) effects of hypertension and Aβ positivity on cognition.

709Here we seek to understand whether subjects with arterial hypertension or Aβ positive status have worse710cognitive performance at baseline (baseline memory, executive function, and PACC5 scores) and outcomes over711time (Δ PACC5). Because both the Aβ and vascular pathologies may exacerbate the formation of WMH and712these, in turn, may also contribute to brain dysfunction and poor cognitive outcomes [5,6,40,41], we also test for713an indirect mediating effect of hypertension and Aβ positivity on cognitive performance via regional WMH714volumes. We adjusted such models for age, sex, education, mean background intensity, and TICV, as described715in 'Covariates, confounders, and data transformation'.

716

717 Figure 2. Posterior WMH probability is associated with both history of arterial hypertension and $A\beta$ 718 positivity.


719 Analysis. We examined the relationship between WMH segmentation maps (outcome) and arterial hypertension 720 and A β positivity (factors) at a voxel level via 2x2 ANCOVA. We accounted for the effects of age, sex, 721 education, mean background intensity, and total intracranial volume. We used an explicit mask to constrain the 722 analysis to voxels in which data for at least five patients were available. *Illustration*. Glass brain projections 723 display regions where we found evidence for a link between WMH probability and hypertension and $A\beta$ 724 positivity (top and middle rows, respectively). In the bottom row, we coloured regions blue if T values for 725 hypertension were greater than for A β positivity and gold otherwise. We thresholded contrast maps at 5% and 726 adjusted p-values for FDR. Findings. Subjects with hypertension had significantly greater WMH volumes 727 throughout the whole brain than those with normotension (peak: superior longitudinal fasciculus, $xyz_{MNI} = [32, -$ 728 1, 18], T = 3.88, DoF = [1.0, 367.0], $p_{FDR} = 0.015$). Moreover, WMH volume was significantly higher in 729 subjects A β positivity versus negativity in posterior regions of the brain, particularly in segments of the forceps 730 major and inferior fronto-occipital fasciculus ($xy_{ZMNI} = [30, -58, 4], T = 5.20, DoF = [1.0, 367.0], p_{FDR} = 0.001$).

731


Figure 3. WMH volume is associated with worse baseline cognitive performance and accelarated decline over time.

734 Analysis. We used multiple linear regression with WMH segmentation maps as the dependent variable and 735 cognitive performance as the independent variable. We accounted for the effects of hypertension, A β positivity, 736 age, sex, education, mean background intensity, and total intracranial volume. We used an explicit mask to 737 constrain the analysis to voxels in which data for at least five patients were available. We thresholded contrast 738 maps at 5% and adjusted p-values for FDR. Illustration. Regression results with memory (top left), executive 739 function (bottom left), PACC5 (top right), and $\Delta PACC5$ (bottom right) as independent variables. Findings. We 740 found WMH to be significantly associated with worse cognitive performance at baseline and sharper decline 741 within a three-year period. Such relationships were consistently evident around portions of the anterior thalamic 742 radiation neighbouring the thalamus (memory: $xyz_{MNI} = [-8, -1, 3], T = 7.00, DoF = [1.0, 366.0], p_{FDR} = 1.44 \times 10^{-10}$ 743 ⁵; executive: $xyz_{MNI} = [-9, 0, 5], T = 6.74, DoF = [1.0, 366.0], p_{FDR} = 2.85 \times 10^{-5}; PACC5: xyz_{MNI} = [-8, 1, 4], T = 10^{-5}; PACC5: xyz_{MNI} = [-8, 1, 4], PACC5: xyz_{MNI} =$ 744 7.20, DoF = [1.0, 366.0], $p_{FDR} = 8.43 \times 10^{-6}$; $\Delta PACC5$: $xy_{ZMNI} = [-7, 2, 2]$, T = 4.53, DoF = [1.0, 217.0], $p_{FDR} = 7.00$, $p_{FDR} = 1.00$, $p_{FDR} =$ 745 5.12×10^{-3}). Frontal and occipital WMH also coincided with a faster cognitive decline (frontal peak at the level 746 of the genu of the corpus callosum: $xyz_{MNI} = [-1, 23, 4], T = 5.19, DoF = [1.0, 217.0], p_{FDR} = 1.37 \times 10^{-3}$; occipital 747 peak at the level of the forceps major and inferior fronto-occipital longitudinal fasciculus: $xy_{ZMNI} = [17, -81, 2]$, 748 $T = 4.69, DoF = [1.0, 217.0], p_{FDR} = 1.23 \times 10^{-2}).$















memor





